Jazz Reports Phase 3 Success for Ziihera in HER2+ GEA
DUBLIN, Ireland, May 27, 2026 Jazz Pharmaceuticals has announced the publication of pivotal Phase 3 HERIZON-GEA-01 trial results in...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
DUBLIN, Ireland, May 27, 2026 Jazz Pharmaceuticals has announced the publication of pivotal Phase 3 HERIZON-GEA-01 trial results in...
HERZLIYA, Israel and CALGARY, Alberta, May 27, 2026 Innocan Pharma Corporation has reported strong first-quarter 2026 financial results, highlighting...
